Type of security: Stock
Sector: Health Care
Industry: Hospital/Nursing Management
The data is delayed by 15 minutes.
Description: DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company offers outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers DaVita Rx, a pharmacy that provides oral medications to patients with ESRD; disease management services; vascular access services; ESRD clinical research programs; physician services; and direct primary care services. As of March 31, 2014, it operated 2,173 outpatient dialysis centers, including 2,098 centers located in the United States; and 75 centers located in 10 countries outside the United
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||-232.26%||EPS Growth - Q/Q||-192.85%|
|EPS Growth - Y/Y||16.12%||Sales Growth - 4 Quarters||3.64%||Sales Growth - Q/Q||-1.2%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||2.34%||ROE||7.37%||ROI||3.12%|
|Current Ratio||1.61||Quick Ratio||1.55||Long Term Debt/Equity||5.17||Debt Ratio||0.46|
|Gross Margin||28.67%||Operating Margin||10.04%||Net Profit Margin||3.29%||Dividend Payout Ratio||-36.74%|
|Cash From Financing Activities||-110.87 M||Cash From Investing Activities||-252.29 M||Cash From Operating Activities||410.09 M||Gross Profit||925.35 M|
|Net Profit||-110.62 M||Operating Profit||-64.16 M||Total Assets||18.37 B||Total Current Assets||4.3 B|
|Total Current Liabilities||2.68 B||Total Debt||8.5 B||Total Liabilities||13.4 B||Total Revenue||3.29 B|
|High 52 week||79.15||Low 52 week||48.73||Last close||58.24||Last change||-0.78%|
|RSI||61.36||Average true range||1.44||Beta||0.63||Volume||417.62 K|
|Simple moving average 20 days||1.59%||Simple moving average 50 days||4.66%||Simple moving average 200 days||-10.22%|
|Performance Week||-1.46%||Performance Month||3.28%||Performance Quart||-0.77%||Performance Half||-17.01%|
|Performance Year||-26.24%||Performance Year-to-date||13.18%||Volatility daily||1.11%||Volatility weekly||2.48%|
|Volatility monthly||5.07%||Volatility yearly||17.58%||Relative Volume||157.6%||Average Volume||1.66 M|
|New High||New Low|
2019-04-18 12:47:03 | Checking in on trade war's impact on the markets
2019-04-16 07:00:00 | Buffett's 'Big Mistake' Is Finally Looking Up
2019-04-14 10:42:36 | Will DaVita Inc.'s NYSE:DVA Earnings Grow In The Year Ahead?
2019-04-10 10:10:02 | Here's Why You Should Hold on to DaVita DVA Stock Now
2019-04-09 14:04:33 | Here’s What Hedge Funds Think About DaVita Inc DVA
2019-04-05 16:24:00 | Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation
2019-03-28 07:30:00 | Consolidated Research: 2019 Summary Expectations for Kinder Morgan, DaVita, Inovalon, Switch, Urban Edge Properties, and The Chefs' Warehouse — Fundamental Analysis, Key Performance Indications
2019-03-25 08:37:12 | Fresenius Medical's New Hemodialysis Software Gets FDA Nod
2019-03-24 14:00:00 | 3 Bargain Stocks You Can Buy Today
2019-03-22 11:23:16 | Jeffry Gates’ Gates Capital Management’s Return, AUM, and Holdings
2019-03-19 10:41:02 | Baxter's BAX New Tie Up to Boost Acute Therapies Business
2019-03-19 01:11:59 | Akebia Therapeutics AKBA Q4 2018 Earnings Conference Call Transcript
2019-03-15 20:45:39 | Kay Properties Completes DST 1031 Offering in Baltimore, Maryland
2019-03-15 09:30:01 | DaVita HealthCare DVA Down 7.8% Since Last Earnings Report: Can It Rebound?
2019-03-13 14:24:07 | How Good Is DaVita Inc. NYSE:DVA, When It Comes To ROE?
2019-03-13 09:45:01 | Should Value Investors Consider DaVita DVA Stock Now?
2019-03-12 10:24:44 | See what the IHS Markit Score report has to say about Davita Inc.
2019-03-08 15:44:15 | 2 Warren Buffett Stocks Trading Near 52-week Lows
2019-03-04 12:23:54 | U.S. seeks to cut dialysis costs with more home care versus clinics
2019-03-04 01:00:00 | FOCUS-U.S. seeks to cut dialysis costs with more home care versus clinics
2019-02-28 14:30:08 | 8 High Margin Stocks to Lead in a Sharply Slowing Economy
2019-02-22 16:48:48 | DaVita Inc DVA Files 10-K for the Fiscal Year Ended on December 31, 2018
2019-02-22 09:16:02 | Here's Why Investors Should Hold DaVita DVA Stock Now
2019-02-19 08:30:01 | New Strong Sell Stocks for February 19th
2019-02-15 07:18:00 | Berkshire Picks Up Red Hat and Suncor, Dumps Oracle
2019-02-15 06:35:14 | 3 Big Stock Charts for Friday: Davita, Fastenal Company and BorgWarner
2019-02-14 14:27:53 | DaVita HealthCare Partners Inc DVA Q4 2018 Earnings Conference Call Transcript
2019-02-14 09:30:02 | Stock Market News For Feb 14, 2019
2019-02-14 07:26:12 | DaVita DVA Q4 Earnings Beat and Revenues Miss Estimates
2019-02-13 18:14:31 | DaVita HealthCare: 4Q Earnings Snapshot
2019-02-13 18:00:11 | DaVita HealthCare DVA Tops Q4 Earnings Estimates
2019-02-13 16:29:00 | DaVita Inc. 4th Quarter 2018 Results
2019-02-12 06:39:11 | What's in the Offing for DaVita DVA This Earnings Season?
2019-02-08 08:00:20 | See what the IHS Markit Score report has to say about Davita Inc.
2019-02-05 08:00:18 | See what the IHS Markit Score report has to say about Davita Inc.
2019-01-30 07:07:00 | DaVita Inc. Schedules 4th Quarter 2018 Investor Conference Call
2019-01-26 12:00:00 | 3 Top Healthcare Stocks to Buy Right Now
2019-01-25 14:10:56 | Should You Investigate DaVita Inc. NYSE:DVA At US$56.39?
2019-01-24 10:07:49 | Denver-based direct primary-care provider more than doubling in size after acquisition
2019-01-22 07:35:00 | Recent Analysis Shows Abercrombie & Fitch, DaVita, W.W. Grainger, Ingredion, FirstEnergy, and Second Sight Medical Products Market Influences — Renewed Outlook, Key Drivers of Growth
2019-01-18 08:02:01 | Baxter BAX Gains From Sharesource's Global Success Rates
2019-01-17 06:01:00 | New Technology Helps Nephrologists Better Manage Patients with Chronic Kidney Disease
2019-01-15 08:00:20 | See what the IHS Markit Score report has to say about Davita Inc.